Optiver Holding
RNAC icon

Optiver Holding’s Cartesian Therapeutics RNAC Stock Holding History

Optiver Holding’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$640 Buy
104
+24
+30% +$171 ﹤0.01% 2135
2025
Q4 		$577 Hold
80
– – ﹤0.01% 2283
2025
Q3 		$818 Buy
+80
New +$899 ﹤0.01% 2522

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Optiver Holding's RNAC Position: Q1 2026 in Review

Optiver Holding increased its Cartesian Therapeutics (RNAC) stake by 30% in Q1 2026, buying an estimated $171 and bringing the position to 104 shares worth $640. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

Optiver Holding first reported a position in RNAC in Q3 2025 and has held it in 3 quarters since. The position peaked at $818 in Q3 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Optiver Holding held 104 shares of Cartesian Therapeutics worth $640 as of Q1 2026.
  • Optiver Holding bought 24 Cartesian Therapeutics shares in Q1 2026, an estimated $171.
  • Cartesian Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #2135 holding.
  • Optiver Holding first reported a position in Cartesian Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Cartesian Therapeutics position peaked at $818 in Q3 2025.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.